Genmab A/S

Hello and welcome to GenMAP's Financial Results Conference Call for the first time in months of 2024. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as beliefs, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. GenMab is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that GenMab may hold your personal data as indicated by you as part of our investor relations outreach activities. In order to update you on GenMab going forward, please refer to our website for more information on GenMab and our privacy policy. I would now like to hand the conference over to your first speaker today, Jan van de Winkel, please go ahead.

Hello and welcome to GENMOB's conference call to discuss the company's financial results for the period ending September 30, 2024. With me today to present these results is our CFO, Anthony Pagano, and we will also welcome our new Chief Commercial Officer, Brad Bailey. For the Q&A, we will also be joined by our Chief Medical Officer, Tai Yamadi, and our Chief Development Officer, Judith Klimovski. Let's move to slide two. As already said, we will be making forward-looking statements, so please keep that in mind as we go through this call. During today's presentation, we will reference products being developed under some of our strategic collaborations. This slide acknowledges those relationships. At GenMob, we have a history of consistent and exceptional success. Eight products, either created by GenMob or via our technology, are currently approved and making a difference in the lives of patients. Of all approved bispecific antibodies, a third of them were created using our dual-body technology. This success allows us to continue our focus on transforming our business in a strategic and stepwise manner, with an eye to the future and how we can best serve patients through our innovative antibody medicines. At the beginning of 2024, AppKindly was the key focus of our late-stage development. Nine months later, we now have two wholly-owned late-stage assets, Rhino-S and Akkasun Limob. Recent events showcase how we are prioritizing the development of these programs, starting with AppKindly. We believe that our validated dual-body technology has given it the best-in-class profile. We are extremely pleased with the launch, especially in Japan, where we have a significant head start over other therapies, and at present, AppKinley is the only approved CD3-CD20 base by Specific. In fact, since launch, we have consistently outperformed our closest competitors globally. In August, AppKinley received its second approval in Europe. That makes it the first and only subcutaneous bispecific antibody approved in both the European Union and the US to treat both relapsed refractory follicular lymphoma and relapsed refractory diffuse large B-cell lymphoma. This demonstrates the potential of abcaritumab to provide a convenient single treatment option across multiple B-cell malignancies. We received additional support for the potential of abkinly in September. with the FDA granting a second breakthrough therapy designation for Epkinley in relapsed refractory follicular lymphoma, this time in combination with rituximab and lenalidomide. With five phase three clinical trials ongoing and more than 20 abstracts accepted at this year's S meeting, including four oral presentations, We and our partner, APFI, remain committed to exploring the development of abcaritumab as a potential core therapy across B-cell malignancies, as demonstrated through the breadth of data presentations this year across forms of lymphoma and lines of therapy. We have also seen recent progress with Reina-S and Akasunimab, our two wholly-owned programs with the potential to be best-in-class therapies. Both of these programs have now moved toward late-stage development with the recent listing of Phase III trials on clinicaltrials.gov. We presented promising dose expansion data in ovarian cancer for Rhin-asset asthma, and we also presented PKPD data at the World Conference on Lung Cancer for Acacunimab that is supportive of our every six-week dosing schedule. We continuously evaluate our clinical pipeline to ensure we are prioritizing our resources in the best and most effective way possible. After careful consideration, we have decided to terminate the early stage clinical programs, GEN1047, GEN3017, and GEN1056. And we will no longer start phase three development for TIFDAC and Second Line Plus head and neck cancer. What should be clear is that our strategic prioritization means we are very focused on maximizing the potential of our phase three programs, APKinley, Rhynas, and Akasunlimab. The number of patients who may benefit from medicines powered by our innovation continues to expand. In September, Amgen's Depessa was approved in Japan, making it the first and only treatment for active thyroid eye disease in the country. J&J achieved multiple approvals for rival funds across the US, Europe, and Japan. And J&J have also expanded Darzalex FastPros indications with additional approvals and a regulatory submission. These developments highlight significant advancements in products that fuel our growing recurring revenues. Brad will now provide you with a review of the recent performance for AppKindly and Tiffdex, both of which have consistent quarter-over-quarter growth. Brad, the floor is yours.

Thank you, Jan. I'm delighted to be joining my first earnings call as Chief Commercial Officer. And over the past several years, we've had a clear focus on building our commercialization capabilities at GenMap. To date, we've been very pleased about a strong performance of our launches in the U.S. and Japan, powered by this strategic investment at work, and this quarter is no different. Specifically, during the third quarter, our commercialization teams executed effectively to deliver our own medicines, Epkinley and TIVDAC, to even more patients worldwide. Epkinley, which is the first and only bispecific approved for both relapsed refractory third-line plus diffuse large B-cell lymphoma and third-line plus follicular lymphoma, closed Q3 with strong performance, reporting 70% growth in the quarter, 82 million in net sales globally, and year-to-date sales of 203 million. Overall, we've continued to see robust uptake across key accounts, strong field execution, and positive responses from physicians and patients. What we're seeing in the field is validating Upkinley's differentiated profile. Most importantly, patients are benefiting from its efficacy, manageable safety, and the seamless experience of subcutaneous administration. In the U.S., Epkinley continues to assert in-class leadership through competitive differentiation and targeted activation with rapid uptake and adoption by key accounts, including a meaningful acceleration following the FL approval. We attribute this performance to three key factors. First and foremost is Epkinley's clinically differentiated profile, which addresses a high unmet need across histologies. We've heard positive feedback from physicians regarding the long-term follow-up data presented at ASCO, underscoring the durability of powerful responses with Epkinley and Thirdline Plus DLBCL. And as John mentioned, we look forward to building upon this with continued follow-up at ASH in December. Second is broad U.S. market accessibility across payers, institutional formularies, and diverse sites of care. Third is the highly effective and well-coordinated execution across our field-based commercialization teams to deliver optimal customer experiences. As we look ahead, brand execution will focus on accelerating adoption and tailoring their approach to account needs. Moving on to Japan, we continue to be pleased with Epcali's performance, with growth largely driven through strong field execution and the broadening types of accounts as activated. As we move to Q4, We will continue to focus on account openings to assure a broad range become familiar with that Kenley ahead of a potential approval in FL. In Europe and the rest of the world, through our partner AbbVie, we also saw strong growth in the third quarter. Turning to TIBDAC, TIBDAC continues to demonstrate strong performance with the 12th consecutive quarter of demand growth and $32 million in sales. The increase in demand is largely driven by the strength and breadth of accounts using TIBDAC. TIVDAC provides unprecedented efficacy where previous options have typically offered low response rates and poor outcomes, and its strong performance with solid year-over-year growth builds a strong foundation to deliver future success in the guideline space. We continue to receive positive feedback from physicians around the results from the innovative 301 confirmatory trial, which demonstrated an overall survival benefit for TIVDAC, with most stating that these data established TIVDAC as the clear standard of care in Second Line Plus recurrent or metastatic cervical cancer globally. As we move ahead, we're focused on capturing more value from our own to commercialized medicines, which represented 35% of GenMAP's overall revenue growth this year. Our foundational investments and our commercialization capabilities are fueling our success and will enable us to scale functions across the business to support our long-term growth. We're building on our momentum expect a successful year-end conclusion. With that, I'll pass it over to Anthony to provide more perspective on our third quarter financials.

Thanks, Brad. We continue to strengthen our foundation throughout the first nine months of the year. We delivered on our goal of multiple successful regulatory approvals and launches for F. Kinley, and we're pleased with how these launches are progressing. We've also significantly enhanced our long-term growth potential with the acquisition of ProfoundBio. And as we'll see, our financials remain strong. Recurring revenues grew by 37%. This was principally driven by strong royalties from Darzalex, Kesimpta, and other approved medicines, as well as strong performance at Kinley and TivDak. Our solid balance sheet, growing recurring revenues, and significant underlying profitability allow us to strategically prioritize our investment, especially in our phase three programs at Kinley, RHNA-S, and at Kusumalamab. Now, let's take a look at those revenues in a bit more detail. We grew total revenue to over 15 billion kroner in the first nine months of the year. And as I've already highlighted, That included a 37% increase in our recurring revenue. This strong growth was driven by higher Darzalex and Cosimta royalties, as well as royalties from other products. Looking at Darzalex specifically, overall, net sales grew by 19%. That's net sales of nearly $8.6 billion, which translates to almost 10 billion kroner in royalty revenue. This growth was driven by continued share gains and strong performance in the frontline setting. And as Brad noted, we're pleased with how Epkinley and Tibdex are performing with consistent growth quarter over quarter. Now, what we're most excited about is that we can see the investments we've made in building out our commercialization teams and capabilities to secure the Epkinley launch are paying off. And this is reflected in our in-class leadership and the strength of our launch in Japan. Taken together, these two products contributed 35% of our total revenue growth in the first nine months. This really illustrates the power of our recurring revenue. And overall, this strong recurring revenue growth enables our continued focused investment in our priorities, as you can see on the next slide. We continue to take a disciplined approach to our investments with a focus on portfolio prioritization and being efficient. Total operating expenses, including profound bioacquisition and integration-related charges, were approximately 9.9 billion kroner. As you can see, the majority of the investment, or 74%, was driven by R&D, and this compares to 71% in the prior year. As you'd expect, given everything we've said about prioritization, we've accelerated investment into advancing our phase three programs at Kinley, RHNA-S, and Atkinson on the map. SG&A growth moderated, up only 8% year over year, reflecting our focus on driving SG&A efficiency. Now, let's take a look at our financials as a whole. Here you can see our summary P&L. Revenue came in at over 15 billion kroner. That's up 29% on last year. Here I want to highlight the improving quality of our revenue profile. In 2024, recurring revenues represented 92% of total revenue compared to 86% over the same period last year. Total OPEX was around $9.9 billion, up 23%. And even with that increased investment, we're still delivering over $4.5 billion of operating profit, and that's up more than 27%. Moving to our net financial items, here we have a net gain of $1 billion. This was driven by a net foreign exchange rate gain as well as by an increase in interest income. Then we have tax expense of around $1.6 billion, which equates to an effective tax rate of 28.1%. And here, I'd note, as I did last quarter, that we continue to evaluate the integration of profound bio operations from a tax perspective. So our effective tax rate may experience some volatility as activities progress. We anticipate this will normalize within the next 12 to 18 months. And that brings us to our net profit of almost 4 billion kroner. So as you can see, continued strong underlying financial performance. Now let's take a look at our guidance. Here, based on strong performance in the first nine months, I'm pleased to say that we've been able to narrow our guidance range with our revenue growth outpacing this year's growth and investment. We are raising the lower end of our revenue range, and this increase is driven by higher royalty revenues from Darzelex. As a result, we now anticipate revenue in the range of 21.1 to 21.7 billion, which is a growth of 30% at the midpoint. Importantly, we continue to anticipate strong growth for our own medicines, with around 1.4 billion kroner of growth from Epkinley and Tibdex. turning now to our operating expenses. Here, we've lowered the upper end of our OpEx range, anticipating 13.7 to 14 billion kroner, excluding acquisition and integration-related charges. This reflects our disciplined approach to investments, as well as rigorous portfolio prioritization. So, as you can see, we continue to deliver on our guidance and prioritization commitments. Taken together, we are generating significant underlying profitability. We're on track to deliver another year of substantial operating profit of between 6.2 to 7.1 billion kroner, excluding acquisition and integration costs. At the midpoint, this represents growth of 25% compared to last year. So in summary, we continue to focus our priorities while consistently delivering on our financial commitments. Now, having covered 2024, let's look ahead a bit to 2025. While guidance will be given in February next year, we are committed to investment in phase three trials for Epkinley, RHNA-S, and Akasunglimab. Now, as I stand here today, Consensus expectations for our investment in 2025 appear to be in a reasonable place, capturing our investment priorities. Now, let me wrap up and provide a few closing remarks. In summary, we are advancing our late stage product portfolio from one to three products while achieving our financial goals through strategically prioritizing our investments. This focused approach enables us to realize our vision and to capitalize on the significant growth opportunities ahead. And with that, I'm going to hand you back over to Jan.

Thank you, Anthony. Let's move now to our final slide. We are very pleased with the progress we have made towards our 2024 goals. Additional approvals have enabled us to expand the reach of AppKindly and TiffDAC. We've strategically advanced our proprietary product portfolio, including the phase three trials for Rhino S and Akka Sunlimab. And in addition to Rhino S, the acquisition of Profound Bio gave us next generation ADC platforms. All of this advanced our evolution into an integrated biotech innovation powerhouse. Finally, for Hexabody CD38, we are in the process of preparing data submissions to J&J. The data package is scheduled to be submitted by the end of December. The opt-in period of 60 days is expected to start in the beginning of January, which means we anticipate a decision from J&J no later than the first quarter of 2025. We will inform the market via press release when J&J has made their decision. This release will include relevant top-line clinical data. To support the integrity of J&J's review process, we will not disclose the information before the official release. Before we move to Q&A, I'm pleased to announce that we will hold our annual R&D updates, and our data review event on December 11. To ensure the event is accessible to as many people as possible, this year's presentations will once again be fully virtual. Details will be available on our website, and we look forward to a lively event. That ends our formal presentation. Operator, please open the call for questions now.

Thank you. To ask a question, you will need to press star 1 and 1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1 and 1 again. We will now go to our first question. One moment, please. And your first question comes from the line of Jonathan Chang. Please go ahead.

Hi, guys. Thanks for taking the questions. First question, just a clarification on the HEXABODY CD38. Did you say that the top line data will be disclosed in the press release when J&J makes a potential opt-in decision or the data package submission press release? And then second question, on RHNA-S, can you discuss the rationale behind not having an FR-alpha expression requirement in the phase three? What's the mechanistic rationale for reNA-S working at low or no FR-alpha expressing patients? Thank you.

Thanks, Jonathan, for the questions. For the Hexabody CD38 top line data, we will announce that once J&J has made the opt-in decision. So we already know the opt-in decision, and then we will release the data, the key data, the key clinical data, Jonathan. So not at the date of submission, but when the opt-in decision is coming in. Then for Raina, I propose that we will move this question to Judith, and Judith can give you further color on the folate receptor alpha expression levels requirements.

Judith? Yes, thank you. So the data presented at ESMO, we showed activity regardless of expression, 75% cutoff or above, which is the approved cutoff for another folate receptor in the market. In addition, there is a footnote that says that we have seen activity in patients that have folate receptor below 25%. So because of the data that we have described, the decision was not to preselect for folate receptor alpha expression.

Thanks, Juliet. Thanks, Jonathan, for the questions.

Thank you. Your next question comes from the line of Michael Schmidt. Please go ahead.

Hi, this is Paul. I'm for Michael. Thanks for taking our question. Maybe just to follow up on Rena S. So for the phase three study, you know, the clinical trials listing doesn't seem to have info on geography yet. So can you talk about how you plan to limit perhaps patients who have been treated with Mervituximab, maybe based on your site distribution? And then my second question is just on TIPDAC and what sort of factors into your decision to discontinue the planned phase three, given your enthusiasm earlier this year, and does that have any impact on how you view the potential in other solid tumors? Thank you.

Thanks, Paul, for the questions. I think Judith can actually start with both questions, and maybe Ty can step in also on the right-hand side. Judith?

Yes, thank you. So for TIBDAG, as Antonia and Ian alluded, it's a strategic decision based on the prioritization of our pipeline and taking into consideration totality of the data, external and internal, but basically a strategic decision based on prioritization of our pipeline. And for RINA-S, I will start by saying that, you know, the approval of mirfetuximab is rolling. So, of course, in some countries where mirfetuximab is not approved, it's not needed, and, you know, it's not standard of care. And on those countries where it is approved, it becomes standard of care, and we have this into consideration for the phase three.

Thanks, Judith.

I don't know, Tai, whether you want to add anything to that or is this okay?

Well, I was just going to add something maybe to the prior question that is like the phenomenon that ADCs with a topo-payload exhibit efficacy in low or ultra-low expressing tumors. It's not necessarily restricted to venous and it's a function, understood to be a function of the linker stability in the payload. and the ability to actually detect, accurately detect the expression of a given target. So as Julia was saying, we have efficacy in low and negative. That is also a function of how you determine low and negative for the receptor alpha positive ovarian cancer. And I was just pointing out that this is not a new phenomenon.

All right. Thanks. Thanks, Tai. I think we can go to the next question operator.

Thank you. Your next question. comes from the line of St. Abraham. Please go ahead.

Hello, St. Abraham, Jake and Morgan. Thank you for taking my questions. Just two for me, please. So my first question is on Gen 1042. So when can we expect to hear from you in terms of next steps for Gen 1042? And is the decision to prioritise TIVDAC and head and neck related to your potential plans for Gen 1042? And then my second question is just on Hexabody CD38 in terms of It's quite helpful in the timeline that you gave us, but just how should we think about the potential safety profile in the head-to-head trial, given the sort of safety signal we saw last year? Based on the baseline recruitment, the baseline characteristics of patients you recruited, do you think that there's a sort of lower risk of any cardiovascular signal coming through in that head-to-head trial? Thank you.

Thanks for the questions. I think I can handle both of them myself. For 1042, we are still collecting more data. And in the next month, we aim to take a decision on next steps. So we will be, in the coming months, when we have collected all that data, different doses and dose frequency, we'll make a decision on next step for the 1042 bispecific program. Then for Hexabody CD38, the data will be released At the time that change, they will have announced or have made their opt-in decision. So we are not going to discuss any other data at this moment. We will just wait until the decision has been taken also to ensure there is no bias in the decision process and there is an optimal way for them to take the decision. But we are very pleased having a very close note to all of the data. And you will hear from that in due time.

Great. Thanks a lot.

Thanks.

Thank you. Your next question comes from the line of . Please go ahead.

Hi, team. Thanks for taking my question. First question in relation to Epigindy and the commercial traction. Can you frame which indications or treatment settings, geographies, or other segments that you're looking at you expect to be potential major drivers? from here for the coming years and remind us how you think about the peak potential of the drug. And then a tiny follow-up on hexabody CD38, very helpful guidance there. But did you also comment on the timeline for the updates you have referred to? Should we still continue to expect something this year? Thank you.

Thanks, Suzanne, for the questions. And the first one I will definitely turn over to Brad. and then see whether I can add further perspective after Brad has given you his input on the commercial potential and where to expect that. The facts about the CD38, we will actually plan to present the data in Q1, Suzanne. Brad, maybe you can answer the question on the kidney commercial potential and the geographies, the countries, et cetera.

Brad, are you there?

He's still connected, sir.

Brad?

Shall I unmute his line from my side if it's possible?

Yeah, please do. Please do. It may be a technical problem. Otherwise, I will.

He is now unmuted, sir.

All right, Brad.

Yes, thank you, operator. My apologies. unable to get the mute off so thank you for the uh for the question and um yeah from uh from an ep kinley perspective obviously um and extremely uh pleased with the work that's been done from a from a u.s and japan perspective and driving over 90 of the revenues at this point in time um certainly the rest of the world with ep kinley we're um we're we're now in a position as we're expanding uh from third line plus vlbcl with potential new approvals in FL as well, and most recently in Europe, and then expected early next year in Japan. So we still see the two major drivers in the U.S. and Japan, with certainly our partner Ampy, as we are in these later lines of therapy that are certainly modest in patient numbers at this point, but certainly as we continue along the development plan, moving into earlier lines of therapy, as well as combinations where we see the value to be increased at that point in time.

So thank you. Thanks. Thanks, Brad, for that call. Hopefully that helps Sison.

Got it.

Thank you.

Thank you.

Thank you. We will now take the next question. And the question comes from the line of Xian Deng. Please go ahead.

Thank you very much. Thank you for taking my questions. Two, please. The first one is on 2025 catalyst. I mean, I understand this is probably a bit too early to give full details for next year's catalyst, but just wondering, you know, on high level, you know, do you think we could expect the acacunumab clinical data follow-up next year? Well, we also see more clinical data on RENIAT, perhaps in combo, as a first question. And the second one is sort of T-stack and the cost related to that. So just wondering, given now you will not progress with the phase three trial, just wondering how much in terms of R&D savings do you expect to come from that? Or the other way of asking this is, could you remind us roughly how big the size of the trial in relationship to the other phase three? Thank you very much.

Thanks, Sian, for the questions. And definitely next year, we will inform you on catalysts early next year when we give guidance for the year, Sian. But definitely for Acacunlimab, we expect further data on the lung cancer setting for sure. And for Reina S., there will surely be data. Both updated data, I think, for the ovarian carcinoma, but also other tumors. So there will definitely be data, and we will let you know early next year what the catalysts are and the approximate timing. And then maybe Anthony Pagano can give you a bit of color on the phase three trial costs for TIFTAC as we anticipated them originally. Anthony?

Yeah, thanks. And I can comment on the investment profile a bit and any additional color either Tahir or Judith, want to provide, we can do after I provide my comments. I think the net here is that we're really focused on prioritizing our portfolio. You heard from Jan today that we've taken four decisions, three on earlier stage programs and one on a later stage program, the TIBDAC program you just noted. This is done with an eye towards really prioritizing our other phase three programs, including at Kinley, Rina S. and Akison Limab. And what I'd leave you with here are two thoughts. This prioritization is something we take very, very seriously and will continue to do. And then the impact of that is reflected in the revised 2024 OPEX guidance, as well as, and it's probably worth repeating, the comments that I made as it relates to 2025. So again, looking ahead to 2025, again, I'll provide guidance in February We're committed to investment in phase three trials for Epkinley, Rina S, and Acosimilamab. Again, as I stand here today, consensus expectations for our investment in 2025 appear to be in a reasonable place. Again, capturing those investment priorities that I just highlighted. So I'm not really in a position to break out the specifics. Again, other than just to highlight for you really our laser-sharp focus on directing the lion's share of our capital in terms of R&D investment to these, particularly the growth to these phase three programs that I just mentioned. Judith, anything you want to highlight regarding that you haven't said already on the TIVDAC program?

No, no, no. I mean, you said it is a strategic decision. And at that time when the decision was made, we were in the planning stage. So the phase three was not fully designed and costed.

It was the prioritization of the portfolio that led to the decisions.

Thanks, Judith. Thank you, Anthony. And you'll see on for the questions, huh? Let's move on to the next one.

Thank you. Your next question comes from the line of Yaron Verba. Please go ahead.

Great. Thanks for taking my question. I just have essentially a follow-up on Gen 1042 and the CD4041BB. So it sounds like you're The way I'm reading you correctly is you're still doing some work on dosing in combination with standard of care and first line. If I remember correctly, it was head and neck, and then you had several other opportunities coming sort of behind, like non-small cell pancreatic and melanoma, and the data is going to be next year. Are you thinking that you're moving to phase three and you'll give us an update on the trial design or kind of what should we expect next year? Thank you.

Thanks for the question. On 1042, we are still collecting data in form-like settings in four different councils, and we believe that we have all the data in hand in the coming months to make a decision on next steps, and we'll let you know at that time.

Thank you.

Let's move to the next question.

Thank you. Your next question comes from the line of Asika Gunawadana. Please go ahead.

Hi, guys. Thanks for taking my question. Jan, I have a quick one on Hexabol C38. Is the data package that you will, final data package that you will send to J&J going to include any of the preclinical data that you explored in autoimmune diseases? And then on RENA-S, Judith, you mentioned the presentation at ASMO, how that had an indication that patients with FRA-alpha less than 25% had clinical activity. Can I attempt you to tell us if you actually saw clinical responses in those patients? Those are my questions. Thanks so much.

Thanks, Astika, for the questions. And Judith can definitely take the second one on Reina S., But for the Hexabody CD38, the data packets will be the clinical head-to-head data, ASTICA, in multiple myeloma, which we'll share with J&J in December. And Judith, maybe you can speak a bit about the Reina S data.

Yes, and ASTICA, thank you for the question. And again, I will refer you to the slide that was presented at the oral presentation at ESMO that shows the waterfall plot with 75% above and below and a footnote that says we saw responses as well in patients below 25%. And we can refer you to the slide number on that oral presentation.

So yes, we saw responses.

Thanks, Judith. And thanks, Asika, for the questions.

Thank you. Your next question comes from the line of .. Please go ahead.

Hi. Thanks for taking my question. I've got one for Reena as we obviously talk about the alpha expression level. And do you see that, my question is, do you see that sort of adaptable into other tumor indication in the sense that you see responses or signals or early signals that the response across different level of alpha expression levels? And how should we think about the opportunities there? Thanks.

Thanks, Yifeng, for the questions. And why don't you ask Tai to start, and then maybe Judith, you can add when you have another few things to, angles to add. Tai?

Well, I mean, without getting too specific, I mean, there obviously is already in the protocol data being generated in, and I think this is clearly publicly disclosed, in endometrial and as well as in a subset of non-small cell lung cancer that is not before it was alpha positive. And there might be opportunity that we'll be able to show some of this data, but we're not going to commit to the timeline when we're going to show that data, when we have the data in our hands. So we're collecting this data as we speak, and when we ... alpha-expressing tumors that are quite obvious and that are already being interrogated as we speak.

Thanks, Tai. Thanks, Yifeng, for the question. Let's move to the next one, operator.

Thank you. Your next question comes from the line of Matt Phipps. Please go ahead.

Thanks for taking my question. Just one quick follow-up on the TIVDAC decision. Are you still planning to evaluate TIVDAC plus Keytruda in the frontline head and neck setting? And then is this part of just a maybe broader shift to incorporate some of the next-gen ADC components from ProfoundBio into programs going forward? Any additional ProfoundBio assets that we should be looking for?

So let me – thanks, Matt, for the questions. Let me ask you to comment on the TIFDAC question, and then I can tell you as it relates to ProfoundBio, we have now two other programs in the clinic as we speak – And the third one, beyond Reina S., which will go to the clinic, a bispecific CMAT-HFR ADC program. We are very, very keen on actually moving forward all of these ADC programs. And then at some point, we may actually also begin to combine some of the immune activator programs like the Akasunimab program with ADCs because we think it makes perfect sense conceptually to start combining those. But we are very excited about the pipeline math. We will see very rapid progress, I think, of the pipeline in the coming time. But in the coming year, we will definitely focus a lot on the late-stage clinical development, the Phase III programs for a number of antibodies. But let me ask Judith to give a call on the K-2 combinations in Frontline.

Yes, thank you. So, as you know, the study TB207 run by Pfizer is ongoing and has a cohort of that is exploring TV in combination with Pembroke in the first line setting.

So you are correct. The cohort is ongoing.

Thanks, Judith. And thanks, Matt.

Please move to the next question.

Thank you. Your next question comes from the line of Alistair Campbell. Please go ahead.

Thanks, Erin. Thanks for taking the question. Thanks for the time. Just a quick follow-up on the Rhino-S trial, just to be clear. Are you going to be testing photoreceptor expression at baseline, and could that be a predefined analysis of the data, or is it simply an all-comers trial? And then just notice your recent collaboration with Revitope. So I'm wondering if you'd discuss what's attracted you to that technology, what do you think that could offer that's different from your own capabilities and bispecifics? Thanks.

Thanks for the questions. The first one on Ryan asked trial, I think a straightforward unit can address that. And maybe, Tai, you can address the second one.

Yeah, so for the first one, I will. So we are not, the study is not preselecting for folate receptor expression. So this is a direct answer. Of course, you know, we are assessing folate receptor expression in every patient, but it's not used to preselect.

Thanks, Gerrit. And then maybe tie in the new deal with the new technology?

Well, generally speaking, we always are looking at outside technologies that complement and enhance our internal capabilities. This is a deal to complement discovery efforts that we're working on to understand how we can expand the opportunity space for T-cell redirection, particularly, but not only vesicle, but particularly also to the solid oncology space where it has, for the most part, been challenging to come up with concepts that are able to replicate the success of T-cell redirection in the heme space, particularly in myeloma and lymphoma. So this is just another component for us to... expand our research opportunities, and it works really well nicely with our CA3 program that we have internally.

Thanks, Thijs. It's actually very complementary and not competitive with our dual-body technology. We believe that this will actually widen the space where we can actually use T-cell engagers. Next question, please.

Thank you. Your next question comes from the line of Vikram Pohit.

Please go ahead.

Hi, good afternoon. Thanks for taking our questions.

So we had two, one on the pipeline discontinuations, one on Ipkimli. So apologies if you mentioned this and we missed it, but the discontinuations you mentioned, are they part of a broader pipeline review? And as a result, can we expect more deprioritizations from the earlier stage efforts you have underway? in the coming quarters. And then secondly, on Epkinley, we're just curious to get your sense on how the profile of patients with DLBCL that you've been treating has been evolving over the past couple of months as the launch has progressed. Thank you.

Thanks for the questions. So let me address the first one. We have actually now really reprioritized our pipeline and we actually have no stop progression of the 1047, 3017 and 1056 programs because these programs simply didn't meet the high bar we have set internally for We're really having a truly differentiated therapeutic candidate. So, yes, we have now, I think, gone through a lot of pipeline reprioritization. In the future, you will again see both new programs added to the pipeline. We recently, for example, added a dual-body POP-alpha DR4 bispecific program with fantastic preclinical data. It's called GEN1057. to the pipeline that started recruiting patients in September. And there will be others starting soon, like the CMAT-HFR ADC program, which is coming from the profound bioacquisition. And we will also potentially close other programs based on data. But this is the pipeline repertorization for now. It is actually very rigorous, and we actually intend to focus more and more on the winners and expand the breadth of the winners in the future. Then for Avkindy, the profile of patients, maybe Brad is the best person to start, and then maybe Ty can add sort of perspective. Brad?

Yes, thanks, Ty. Thanks, Jan. Thanks for the question. And we certainly continue to hear from HCPs regarding the types of patients about their positive clinical experiences across both DLBCL and now FL, certainly further validating our differentiated profile in the sub-Q administration as well and the ease of administration. sort of past the initial phase of the launch period, we're now hearing that the types of patients are evolving into the true, and so multiple later lines of therapy into the true third line plus setting in DLBCL. And with FL, it's a little too early to accurately assess any type of unique patients at this point, but continue to hear favorable responses from our providers.

Thanks, Brad. Ty, do you want to add anything to that?

Well, I mean, I was just generally saying I think there is a continuous evidence that the initial hypothesis that the subcutaneous administration from a patient convenience point of view, but also from a safety point of view, would play out well and would expand access to this modality for patients. I think it's fair to say that this is playing out every day.

Thanks, Ty. And what I can also say is that we are seeing really, really good data in broader and broader patient populations, also in clinical trials, Vikram. I can tell you that also the CLL data has been selected for the ASPRESS program on December the 8th. It's one of the very few programs with abcaritumab. So we also see some very good data in CLL. And then when you look at the oral presentations at ASH, you can look at the abstracts for now. We see actually a better and better profile, suggesting that abcaritumab is clearly a best-in-class, having a best-in-class profile in different B-cell cancers. So we are very excited about the potential. We're going to broaden and maximize the potential of B-cells abcaritumab program together with our partner, APFI, over the coming time. So more to come in early December at ASH. And also, I think one of the highlights is on December the 8th in the ASPRESS program, which will feature, amongst other programs, abcaritumab treatment of patients with CLL.

Got it. Thank you very much. Very helpful.

All right. Thank you for the question.

Thank you. We will now take our final question for today. And your final question comes from the line of Etta Darut. Please go ahead.

Great. Thanks for taking the question. Just given the portfolio review, just wondered if you had any updated thoughts on the platform in autoimmune disease, you know, sort of given, you know, what we're hearing about CD38 and OX40 in development, just your kind of overall thoughts given sort of your platform, antibody platform, and some of the enthusiasm around some of these mechanisms in autoimmune. Thanks.

Thanks, Edsel, for the questions. And I will start here, then Ty and Judith, don't hesitate to step in then with more perspective. We still have a very active number of programs in preclinical development, Edsel, and autoimmune indications, either with ourselves or with ourselves in combination with Argenix, where we are working on a number of programs in the autoimmune area, also using our next-generation antibody technology platforms. And, of course, there is potential to potentially move also with ADC technologies towards autoimmune. And we definitely have a number of preclinical scenarios we are working on but they are not yet ready for clinical introduction. So the majority of the work at GENMAP over the coming years will still be in cancer, where we have our dominant focus, but we are clearly very interested in exploring innovative ways to move towards autoimmune with T-cell engagement programs, potentially ADCs, or other next-generation antibody technologies. This year, we will also see the clinical validation of the Hexabody program via our Hexabody CD38 approach, but that is right now in multiple myeloma. But that, I think, has also potential in autoimmune-type settings. But more to come in the future. Ty, Jure, do you want to add anything to that?

I think you summarized it very well.

Thank you.

Thank you, Jan.

All right, Judith Tsai. So thanks, Edsel, for the questions. And more to come in the future. Thank you.

Thank you, Ed. Sorry, Ed. The floor is yours.

Yeah, thank you very much, operator. So thank you all for calling in today to discuss GenMod financial results for the first nine months of 2024. If you have any additional questions, please reach out to our investor relations team. We hope that you all stay safe and keep optimistic. And we very much look forward to speaking with you all again soon.

Thank you. This concludes today's conference call. Thanks for participating. You may now disconnect.